



- (51) **International Patent Classification:**  
*C07K 14/05* (2006.01)
- (21) **International Application Number:**  
PCT/GB2014/052464
- (22) **International Filing Date:**  
12 August 2014 (12.08.2014)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**  
1314404.3 12 August 2013 (12.08.2013) GB
- (71) **Applicant:** IMMUNOCORE LIMITED [GB/GB]; 91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).
- (72) **Inventors:** SU, Qin; 91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). MOLLOY, Peter; 91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB). LIDDY, Nathaniel; 91 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY (GB).
- (74) **Agent:** LEE, Nicholas; Kilburn & Strode LLP, 20 Red Lion Street, London, Greater London WC1R 4PJ (GB).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

**Published:**

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) **Title:** T CELL RECEPTORS

(57) **Abstract:** The present invention relates to T cell receptors (TCRs) which bind the HLA-A2 restricted CLGGLTMTV peptide derived from the LMP2A protein from Epstein Barr Virus (EBV). TCRs of the invention comprise a TCR alpha chain variable domain and/or a TCR beta variable domain. Certain preferred TCRs also bind the natural peptide variants SLGGLTMTV and CLGGLITMV presented as a peptide-HLA-A2 complex. The TCRs of the invention demonstrate excellent specificity profiles for those LMP2A epitopes and have binding affinities for the complex which result in an enhanced ability to recognize the complex compared to a soluble reference TCR having the extracellular sequence of the native EBV LMP2A TCR alpha chain given in Figure 3 (SEQ ID No: 4) and the extracellular sequence of the native EBV LMP2A TCR beta chain given in Figure 4 (SEQ ID No: 5)



WO 2015/022520 A1